WALTHAM, Mass.-- (BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

– Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025 – – Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT ...

Deciphera Pharmaceuticals’ DCPH shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a definitive merger agreement with ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical (OTCMKTS:OPHLY). This deal has ONO acquiring ...

Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy. As of August 2, 2023, the average one-year price target for ...

Deciphera is seeking NCCN guideline inclusion of Qinlock as a second-line treatment for GIST despite a phase 3 trial flop. (NeoLeo/iStock/Getty Images Plus) Deciphera Pharmaceuticals recently took a ...

This incredible daily move in DCPH stock is notable for a few reasons. Over the past month, prior to today, Deciphera had seen some rather bullish momentum. This was a biopharmaceutical stock with ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings within the last quarter: According to 8 analyst offering 12-month price targets in the last 3 months, Deciphera ...